tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Jefferies says Galafold summary judgment as expected, may facilitate settlement
PremiumThe FlyJefferies says Galafold summary judgment as expected, may facilitate settlement
1M ago
Amicus presents four-year data from PROPEL study of Pombiliti, Opfolda
Premium
The Fly
Amicus presents four-year data from PROPEL study of Pombiliti, Opfolda
1M ago
Amicus’s Strong Performance and Growth Potential Drive Buy Rating
Premium
Ratings
Amicus’s Strong Performance and Growth Potential Drive Buy Rating
3M ago
Amicus Therapeutics Reports Strong Q2 2025 Growth
PremiumCompany AnnouncementsAmicus Therapeutics Reports Strong Q2 2025 Growth
3M ago
Amicus Therapeutics: Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
Premium
Ratings
Amicus Therapeutics: Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
3M ago
Amicus Therapeutics: Strong Q2 Performance Amid Competitive Uncertainties Warrants Hold Rating
Premium
Ratings
Amicus Therapeutics: Strong Q2 Performance Amid Competitive Uncertainties Warrants Hold Rating
3M ago
Amicus upgraded to Overweight from Equal Weight at Morgan Stanley
PremiumThe FlyAmicus upgraded to Overweight from Equal Weight at Morgan Stanley
3M ago
Amicus upgraded to Overweight from Equal Weight at Morgan Stanley
Premium
The Fly
Amicus upgraded to Overweight from Equal Weight at Morgan Stanley
3M ago
Amicus announces approval of Pombiliti + Opfolda in Japan
Premium
The Fly
Amicus announces approval of Pombiliti + Opfolda in Japan
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100